ARVN
Arvinas Inc
1 day chart
About ARVN
Arvinas, Inc. is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of therapies that degrade disease-causing proteins. The Company uses its proteolysis targeting chimera (PROTAC) Discovery Engine, a technology platform to engineer PROTAC targeted protein degraders that are designed to harness the body’s own natural protein disposal system to selectively remove disease-causing proteins. Its three product candidates include ARV-110, ARV-471 and ARV-766. It develops ARV-110, a PROTAC protein degrader targeting the androgen receptor protein (AR), for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). It develops ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein (ER), for the treatment of patients with locally advanced or metastatic ER-positive/HER2 negative breast cancer. The Company develops ARV-766, a PROTAC protein degrader for the treatment of men with mCRPC.
Buy US stocks in Australia starting with ARVN. Open an account and start investing today!
$1.35B
-
0.00%
935K
$25.34
$23.89
$25.34
$57.96
$21.21
ARVN FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in ARVN
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.